Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Novel Approaches to Exploiting Invariant NKT Cells in Cancer Immunotherapy.

Wolf BJ, Choi JE, Exley MA.

Front Immunol. 2018 Mar 2;9:384. doi: 10.3389/fimmu.2018.00384. eCollection 2018. Review.

2.

IAP Antagonists Enhance Cytokine Production from Mouse and Human iNKT Cells.

Clancy-Thompson E, Ali L, Bruck PT, Exley MA, Blumberg RS, Dranoff G, Dougan M, Dougan SK.

Cancer Immunol Res. 2018 Jan;6(1):25-35. doi: 10.1158/2326-6066.CIR-17-0490. Epub 2017 Nov 29.

PMID:
29187357
3.

Isolation and Functional Use of Human NKT Cells.

Exley MA, Wilson SB, Balk SP.

Curr Protoc Immunol. 2017 Nov 1;119:14.11.1-14.11.20. doi: 10.1002/cpim.33.

PMID:
29091262
4.

Overview: NK-cell-based Immunotherapies: Toward & Into Clinical Trials.

Exley MA, Orange JS.

Clin Immunol. 2017 Apr;177:1-2. doi: 10.1016/j.clim.2017.05.004. No abstract available.

PMID:
28583665
5.

Adipose Type One Innate Lymphoid Cells Regulate Macrophage Homeostasis through Targeted Cytotoxicity.

Boulenouar S, Michelet X, Duquette D, Alvarez D, Hogan AE, Dold C, O'Connor D, Stutte S, Tavakkoli A, Winters D, Exley MA, O'Shea D, Brenner MB, von Andrian U, Lynch L.

Immunity. 2017 Feb 21;46(2):273-286. doi: 10.1016/j.immuni.2017.01.008.

6.

The role of natural killer T cells in a mouse model with spontaneous bile duct inflammation.

Schrumpf E, Jiang X, Zeissig S, Pollheimer MJ, Anmarkrud JA, Tan C, Exley MA, Karlsen TH, Blumberg RS, Melum E.

Physiol Rep. 2017 Feb;5(4). pii: e13117. doi: 10.14814/phy2.13117.

7.

Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial.

Exley MA, Friedlander P, Alatrakchi N, Vriend L, Yue S, Sasada T, Zeng W, Mizukami Y, Clark J, Nemer D, LeClair K, Canning C, Daley H, Dranoff G, Giobbie-Hurder A, Hodi FS, Ritz J, Balk SP.

Clin Cancer Res. 2017 Jul 15;23(14):3510-3519. doi: 10.1158/1078-0432.CCR-16-0600. Epub 2017 Feb 13.

PMID:
28193627
8.

What rheumatologists need to know about innate lymphocytes.

Exley MA, Tsokos GC, Mills KH, Elewaut D, Mulhearn B.

Nat Rev Rheumatol. 2016 Nov;12(11):658-668. doi: 10.1038/nrrheum.2016.140. Epub 2016 Sep 2. Review.

PMID:
27586381
9.

What Makes MAITs Wait?

Exley MA.

Immunity. 2016 Jan 19;44(1):7-9. doi: 10.1016/j.immuni.2015.12.021.

10.

A Subset of CD8αβ+ Invariant NKT Cells in a Humanized Mouse Model.

Wen X, Kim S, Xiong R, Li M, Lawrenczyk A, Huang X, Chen SY, Rao P, Besra GS, Dellabona P, Casorati G, Porcelli SA, Akbari O, Exley MA, Yuan W.

J Immunol. 2015 Aug 15;195(4):1459-69. doi: 10.4049/jimmunol.1500574. Epub 2015 Jul 8.

11.

Adoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015.

Gilham DE, Anderson J, Bridgeman JS, Hawkins RE, Exley MA, Stauss H, Maher J, Pule M, Sewell AK, Bendle G, Lee S, Qasim W, Thrasher A, Morris E.

Hum Gene Ther. 2015 May;26(5):276-85. doi: 10.1089/hum.2015.024. Review.

12.

The biliary epithelium presents antigens to and activates natural killer T cells.

Schrumpf E, Tan C, Karlsen TH, Sponheim J, Björkström NK, Sundnes O, Alfsnes K, Kaser A, Jefferson DM, Ueno Y, Eide TJ, Haraldsen G, Zeissig S, Exley MA, Blumberg RS, Melum E.

Hepatology. 2015 Oct;62(4):1249-59. doi: 10.1002/hep.27840. Epub 2015 May 20.

13.

Invariant Natural Killer T Cells are Reduced in Hereditary Hemochromatosis Patients.

Maia ML, Pereira CS, Melo G, Pinheiro I, Exley MA, Porto G, Macedo MF.

J Clin Immunol. 2015 Jan;35(1):68-74. doi: 10.1007/s10875-014-0118-0. Epub 2014 Dec 6.

PMID:
25479931
14.

Interplay between the immune system and adipose tissue in obesity.

Exley MA, Hand L, O'Shea D, Lynch L.

J Endocrinol. 2014 Nov;223(2):R41-8. doi: 10.1530/JOE-13-0516. Epub 2014 Sep 16. Review.

15.

Involvement of the iNKT cell pathway is associated with early-onset eosinophilic esophagitis and response to allergen avoidance therapy.

Lexmond WS, Neves JF, Nurko S, Olszak T, Exley MA, Blumberg RS, Fiebiger E.

Am J Gastroenterol. 2014 May;109(5):646-57. doi: 10.1038/ajg.2014.12. Epub 2014 Feb 11.

16.

CD1d favors MHC neighborhood, GM1 ganglioside proximity and low detergent sensitive membrane regions on the surface of B lymphocytes.

Shrestha D, Exley MA, Vereb G, Szöllősi J, Jenei A.

Biochim Biophys Acta. 2013 Oct 25. pii: S0304-4165(13)00470-4. doi: 10.1016/j.bbagen.2013.10.030. [Epub ahead of print]

PMID:
24513453
17.

CD1d favors MHC neighborhood, GM1 ganglioside proximity and low detergent sensitive membrane regions on the surface of B lymphocytes.

Shrestha D, Exley MA, Vereb G, Szöllősi J, Jenei A.

Biochim Biophys Acta. 2014 Jan;1840(1):667-80.

PMID:
24482817
18.

Human invariant NKT cell subsets differentially promote differentiation, antibody production, and T cell stimulation by B cells in vitro.

Zeng SG, Ghnewa YG, O'Reilly VP, Lyons VG, Atzberger A, Hogan AE, Exley MA, Doherty DG.

J Immunol. 2013 Aug 15;191(4):1666-76. doi: 10.4049/jimmunol.1202223. Epub 2013 Jul 12.

19.

Ex vivo analysis of resident hepatic pro-inflammatory CD1d-reactive T cells and hepatocyte surface CD1d expression in hepatitis C.

Yanagisawa K, Yue S, van der Vliet HJ, Wang R, Alatrakchi N, Golden-Mason L, Schuppan D, Koziel MJ, Rosen HR, Exley MA.

J Viral Hepat. 2013 Aug;20(8):556-65. doi: 10.1111/jvh.12081. Epub 2013 Mar 11.

20.

Cutting edge: CD1d restriction and Th1/Th2/Th17 cytokine secretion by human Vδ3 T cells.

Mangan BA, Dunne MR, O'Reilly VP, Dunne PJ, Exley MA, O'Shea D, Scotet E, Hogan AE, Doherty DG.

J Immunol. 2013 Jul 1;191(1):30-4. doi: 10.4049/jimmunol.1300121. Epub 2013 Jun 5.

21.

Loss of effector and anti-inflammatory natural killer T lymphocyte function in pathogenic simian immunodeficiency virus infection.

Rout N, Greene J, Yue S, O'Connor D, Johnson RP, Else JG, Exley MA, Kaur A.

PLoS Pathog. 2012 Sep;8(9):e1002928. doi: 10.1371/journal.ppat.1002928. Epub 2012 Sep 20.

22.

Adipose tissue invariant NKT cells protect against diet-induced obesity and metabolic disorder through regulatory cytokine production.

Lynch L, Nowak M, Varghese B, Clark J, Hogan AE, Toxavidis V, Balk SP, O'Shea D, O'Farrelly C, Exley MA.

Immunity. 2012 Sep 21;37(3):574-87. doi: 10.1016/j.immuni.2012.06.016. Epub 2012 Sep 13.

23.

Hepatitis C virus-specific T-cell-derived transforming growth factor beta is associated with slow hepatic fibrogenesis.

Li S, Vriend LE, Nasser IA, Popov Y, Afdhal NH, Koziel MJ, Schuppan D, Exley MA, Alatrakchi N.

Hepatology. 2012 Dec;56(6):2094-105. doi: 10.1002/hep.25951.

24.

Editorial: NKT get the 'flu: NKT cells as (mostly) good guys in influenza; monocytic cells as double agents.

Exley MA.

J Leukoc Biol. 2012 Mar;91(3):349-52. doi: 10.1189/jlb.0911468. No abstract available.

PMID:
22379073
25.

Protective role of regulatory decidual γδ T cells in pregnancy.

Exley MA, Boyson JE.

Clin Immunol. 2011 Dec;141(3):236-9. doi: 10.1016/j.clim.2011.09.004. Epub 2011 Sep 16. No abstract available.

PMID:
21996457
26.

Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects.

Exley MA, Lynch L, Varghese B, Nowak M, Alatrakchi N, Balk SP.

Clin Immunol. 2011 Aug;140(2):184-95. doi: 10.1016/j.clim.2011.04.017. Epub 2011 May 13. Review.

27.

NKT-cell-based immunotherapies in clinical trials.

Exley MA, Nakayama T.

Clin Immunol. 2011 Aug;140(2):117-8. doi: 10.1016/j.clim.2011.04.015. Epub 2011 Apr 28. No abstract available.

PMID:
21592864
28.

Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.

Hogan AE, O'Reilly V, Dunne MR, Dere RT, Zeng SG, O'Brien C, Amu S, Fallon PG, Exley MA, O'Farrelly C, Zhu X, Doherty DG.

Clin Immunol. 2011 Aug;140(2):196-207. doi: 10.1016/j.clim.2011.03.016. Epub 2011 Apr 13.

PMID:
21493160
29.

Nuancing the proposed role of NKT cells in aging.

Schneiders FL, de Bruin R, Exley MA, van der Vliet HJ.

Virulence. 2011 Mar-Apr;2(2):170; author reply 171. Epub 2011 Mar 1. No abstract available.

PMID:
21304268
30.

HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells.

Song W, Tai YT, Tian Z, Hideshima T, Chauhan D, Nanjappa P, Exley MA, Anderson KC, Munshi NC.

Leukemia. 2011 Jan;25(1):161-8. doi: 10.1038/leu.2010.244. Epub 2010 Nov 19.

31.

Isolation and functional use of human NKT cells.

Exley MA, Wilson B, Balk SP.

Curr Protoc Immunol. 2010 Aug;Chapter 14:Unit 14.11. doi: 10.1002/0471142735.im1411s90.

PMID:
20814940
32.

Comment on "Essential Role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung".

Budd R, Huber S, Exley MA.

J Immunol. 2010 Aug 15;185(4):1991; author reply 1991-2. doi: 10.4049/jimmunol.1090071. No abstract available.

33.

Heterogeneity in phenotype and function of CD8+ and CD4/CD8 double-negative Natural Killer T cell subsets in sooty mangabeys.

Rout N, Else JG, Yue S, Connole M, Exley MA, Kaur A.

J Med Primatol. 2010 Aug;39(4):224-34. doi: 10.1111/j.1600-0684.2010.00431.x.

34.

Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with α-galactosylceramide.

Nowak M, Arredouani MS, Tun-Kyi A, Schmidt-Wolf I, Sanda MG, Balk SP, Exley MA.

PLoS One. 2010 Jun 25;5(6):e11311. doi: 10.1371/journal.pone.0011311.

35.

Primary deficiency of microsomal triglyceride transfer protein in human abetalipoproteinemia is associated with loss of CD1 function.

Zeissig S, Dougan SK, Barral DC, Junker Y, Chen Z, Kaser A, Ho M, Mandel H, McIntyre A, Kennedy SM, Painter GF, Veerapen N, Besra GS, Cerundolo V, Yue S, Beladi S, Behar SM, Chen X, Gumperz JE, Breckpot K, Raper A, Baer A, Exley MA, Hegele RA, Cuchel M, Rader DJ, Davidson NO, Blumberg RS.

J Clin Invest. 2010 Aug;120(8):2889-99. doi: 10.1172/JCI42703. Epub 2010 Jul 1.

36.

Paucity of CD4+ natural killer T (NKT) lymphocytes in sooty mangabeys is associated with lack of NKT cell depletion after SIV infection.

Rout N, Else JG, Yue S, Connole M, Exley MA, Kaur A.

PLoS One. 2010 Mar 24;5(3):e9787. doi: 10.1371/journal.pone.0009787.

37.

The A2aR adenosine receptor controls cytokine production in iNKT cells.

Nowak M, Lynch L, Yue S, Ohta A, Sitkovsky M, Balk SP, Exley MA.

Eur J Immunol. 2010 Mar;40(3):682-7. doi: 10.1002/eji.200939897.

38.

Direct CD1d-mediated stimulation of APC IL-12 production and protective immune response to virus infection in vivo.

Yue SC, Nowak M, Shaulov-Kask A, Wang R, Yue D, Balk SP, Exley MA.

J Immunol. 2010 Jan 1;184(1):268-76. doi: 10.4049/jimmunol.0800924. Epub 2009 Nov 30.

39.

CD1d-based combination therapy eradicates established tumors in mice.

Teng MW, Sharkey J, McLaughlin NM, Exley MA, Smyth MJ.

J Immunol. 2009 Aug 1;183(3):1911-20. doi: 10.4049/jimmunol.0900796.

40.

CD1d activation and blockade: a new antitumor strategy.

Teng MW, Yue S, Sharkey J, Exley MA, Smyth MJ.

J Immunol. 2009 Mar 15;182(6):3366-71. doi: 10.4049/jimmunol.0802964.

41.

Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy.

Song W, van der Vliet HJ, Tai YT, Prabhala R, Wang R, Podar K, Catley L, Shammas MA, Anderson KC, Balk SP, Exley MA, Munshi NC.

Clin Cancer Res. 2008 Nov 1;14(21):6955-62. doi: 10.1158/1078-0432.CCR-07-5290.

42.

Selective activation, expansion, and monitoring of human iNKT cells with a monoclonal antibody specific for the TCR alpha-chain CDR3 loop.

Exley MA, Hou R, Shaulov A, Tonti E, Dellabona P, Casorati G, Akbari O, Akman HO, Greenfield EA, Gumperz JE, Boyson JE, Balk SP, Wilson SB.

Eur J Immunol. 2008 Jun;38(6):1756-66. doi: 10.1002/eji.200737389.

43.
44.

Isolation and functional use of human NK T cells.

Exley MA, Balk SP, Wilson SB.

Curr Protoc Immunol. 2003 Feb;Chapter 14:Unit 14.11. doi: 10.1002/0471142735.im1411s52. Review.

PMID:
18432899
45.

Peripheral blood progenitor cell product contains Th1-biased noninvariant CD1d-reactive natural killer T cells: implications for posttransplant survival.

Shaulov A, Yue S, Wang R, Joyce RM, Balk SP, Kim HT, Avigan DE, Uhl L, Sackstein R, Exley MA.

Exp Hematol. 2008 Apr;36(4):464-72. doi: 10.1016/j.exphem.2007.12.010. Epub 2008 Feb 8.

46.

Invariant natural killer T cells from rhesus macaque spleen and peripheral blood are phenotypically and functionally distinct populations.

Gansuvd B, Goodwin J, Asiedu CK, Jiang XL, Jargal U, Andrades P, Exley MA, Thomas JM.

J Med Primatol. 2008 Feb;37(1):1-11. doi: 10.1111/j.1600-0684.2007.00222.x.

PMID:
18199066
47.

Exploiting regulatory T-cell populations for the immunotherapy of cancer.

van der Vliet HJ, Koon HB, Atkins MB, Balk SP, Exley MA.

J Immunother. 2007 Sep;30(6):591-5. Review.

PMID:
17667522
48.

Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer.

van der Vliet HJ, Koon HB, Yue SC, Uzunparmak B, Seery V, Gavin MA, Rudensky AY, Atkins MB, Balk SP, Exley MA.

Clin Cancer Res. 2007 Apr 1;13(7):2100-8. Erratum in: Clin Cancer Res. 2007 Jun 1;13(11):3433. van der Vliet, Hans J J [corrected to van der Vliet, Hans J].

49.

Hepatitis C virus (HCV)-specific CD8+ cells produce transforming growth factor beta that can suppress HCV-specific T-cell responses.

Alatrakchi N, Graham CS, van der Vliet HJ, Sherman KE, Exley MA, Koziel MJ.

J Virol. 2007 Jun;81(11):5882-92. Epub 2007 Mar 21.

50.

Implications for invariant natural killer T cell ligands due to the restricted presence of isoglobotrihexosylceramide in mammals.

Speak AO, Salio M, Neville DC, Fontaine J, Priestman DA, Platt N, Heare T, Butters TD, Dwek RA, Trottein F, Exley MA, Cerundolo V, Platt FM.

Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5971-6. Epub 2007 Mar 19.

Supplemental Content

Loading ...
Support Center